{"disease":{"id":"core-binding-factor-acute-myeloid-leukemia","name":"core binding factor acute myeloid leukemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06917911","title":"Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":162,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05404516","title":"Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":88,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT01238211","title":"Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05821738","title":"Avapritinib in CBF-AML With KIT Mutations","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03686345","title":"Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":34,"lead_sponsor_name":"Niguarda Hospital","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}